Payment overview · 2025
General Payments
$4,434.50
71 reported records · 22 companies
Healthcare provider profile · identity verified
Javier A. Lafuente, M.D.
Allopathic & Osteopathic Physicians|Transplant Surgery · HOUSTON, TX · NPI 1467481721
Verified facts
What the public records show
CMS Open Payments records show Javier A. Lafuente, M.D. received $4,434.50 in general payments during 2025 across 71 reported records.
Medtronic, Inc. accounted for 60.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$2,664.29 | 60.1% | 28 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $408.67 | 9.2% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $193.70 | 4.4% | 1 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $154.27 | 3.5% | 2 | 2025 |
| Medinc of Texas | Unresolved — no canonical attribution shown | $152.24 | 3.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $144.66 | 3.3% | 9 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $135.37 | 3.0% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $112.60 | 2.5% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $92.51 | 2.1% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $61.61 | 1.4% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $44.86 | 1.0% | 1 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $34.05 | 0.8% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $30.85 | 0.7% | 1 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $30.56 | 0.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.53 | 0.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.08 | 0.5% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $22.23 | 0.5% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $22.01 | 0.5% | 1 | 2025 |
| EnableCV Inc. | Unresolved — no canonical attribution shown | $21.53 | 0.5% | 1 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $21.29 | 0.5% | 1 | 2025 |
| Dilon Technologies, Inc. | Unresolved — no canonical attribution shown | $20.40 | 0.5% | 1 | 2025 |
| On Target Laboratories, Inc | Unresolved — no canonical attribution shown | $15.19 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,954.60 | 61 |
| Travel and Lodging | $1,479.90 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $2,569.72 | 24 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $193.70 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $178.19 | 7 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $154.27 | 2 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $154.27 | 2 | 2025 |
Source payment records
|
|||||
| PREVELEAK Normalized: preveleak |
Device | Baxter Healthcare | $135.37 | 1 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $112.60 | 1 | 2025 |
Source payment records
|
|||||
| ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM Normalized: atricure cryoice cryosphere cryoablation system |
Device | AtriCure, Inc. | $112.60 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $92.51 | 1 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $61.61 | 3 | 2025 |
Source payment records
|
|||||
| AVALUS Normalized: avalus |
Device | Medtronic, Inc. | $50.27 | 2 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $44.53 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $34.05 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $34.05 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $34.05 | 1 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $34.05 | 1 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $34.05 | 1 | 2025 |
Source payment records
|
|||||
| FIBRYGA Normalized: fibryga |
Biological | Octapharma USA, Inc. | $30.85 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $30.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $27.53 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.53 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Stent Normalized: enroute transcarotid stent |
Device | Boston Scientific Corporation | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| SIGNIA Normalized: signia |
Device | Medtronic, Inc. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $22.25 | 2 | 2025 |
Source payment records
|
|||||
| CLEVIPREX Normalized: cleviprex |
Drug | Chiesi USA, Inc. | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C. VERAFLO Normalized: v a c veraflo |
Device | Solventum Corporation | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| THRUPORT SYSTEMS INTRACLUDE INTRA-AORTIC OCCLUSION DEVICE Normalized: thruport systems intraclude intra aortic occlusion device |
Device | EnableCV Inc. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| ETHICON Normalized: ethicon |
Device | Ethicon US, LLC | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| SURGIFLO Hemostatic Matrix Normalized: surgiflo hemostatic matrix |
Device | Ethicon US, LLC | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| HEMOBLAST BELLOWS Normalized: hemoblast bellows |
Device | Dilon Technologies, Inc. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| AngioJet Ultra 5000A Normalized: angiojet ultra 5000a |
Device | Boston Scientific Corporation | $19.63 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRIS RESILIA AORTIC VALVE Normalized: inspiris resilia aortic valve |
Device | Edwards Lifesciences Corporation | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| JETSTREAM SC Normalized: jetstream sc |
Device | Boston Scientific Corporation | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| Cytalux Normalized: cytalux |
Drug | On Target Laboratories, Inc | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| EkoSonic Normalized: ekosonic |
Device | Boston Scientific Corporation | $12.49 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $3.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,434.50 · 71 records | Medtronic, Inc. | ARTEGRAFT VASCULAR GRAFT, ATRICLIP LAA EXCLUSION SYSTEM, ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM, AVALUS, AngioJet Ultra 5000A, BodyGuardian, CLEVIPREX, COREVALVE EVOLUT R, Cytalux, ELIQUIS, ENDOCROSS Device, ENDURANT IIS, ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent, ETHICON, EkoSonic, FIBRYGA, GORE VIABAHN VBX Balloon Expandable Endo, HEMOBLAST BELLOWS, INSPIRE, INSPIRIS RESILIA AORTIC VALVE, JETSTREAM SC, NAVITOR, NURTEC ODT, PREVELEAK, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, SAPIEN 3 Ultra RESILIA, SIGNIA, SURGIFLO Hemostatic Matrix, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, THRUPORT SYSTEMS INTRACLUDE INTRA-AORTIC OCCLUSION DEVICE, Torus Stent Graft System, V.A.C. VERAFLO, VISTASEAL, Varithena Administration Pack, ZENITH SPIRAL-Z | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error